Replicor Inc.
This article was originally published in Start Up
Executive Summary
Spun-out of McGill University, Replicor is modulating DNA replication for better gene therapies and to influence cell proliferation for cancer or tissue engineering.
You may also be interested in...
Canadian Start-Ups: Academics Become Entrepreneurs
By rewarding ownership, Canada is attempting to keep its arms around native technology. Canadian companies are recompensed by R&D tax credits at the federal and provincial levels and individual investors get R&D tax credits for long-term investing in Canadian firms. Recenty, $2 billion in venture funding has come into the life sciences industry. To capture this new funding, entrepreneurs have emerged from academic laboratories, creating more than 200 new biotech companies since 1994.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.